The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.

Rachel Peaytt,Laura Beth Parsons, Darby Siler, Rachel Matthews, Belinda Li,David Bell,Carlos Bachier,Jeremy Pantin,Jesus Berdeja,Ian Flinn,William Donnellan,Minoo Battiwalla

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）

引用 0|浏览6

暂无评分

摘要

Earlier onset of fever appears to be associated with more severe, progressive cytokine release syndrome requiring multiple doses of anti-interleukin-6 therapy. Prompt and aggressive tocilizumab treatment could be protective against the negative consequences of cytokine release syndrome.

查看译文

关键词

chimeric antigen receptor t-cell therapy,cytokine release syndrome,immune effector cell therapy,interleukin-6,tocilizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要